Q-omics provides the consensus-scored TRBV10-2 profile across patient tissues and cancer cell-line models. TRBV10-2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRBV10-2 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, TRBV10-2 RNA expression shows 15,360 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, KIRC, and PDAC as cancer lineages where TRBV10-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBV10-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBV10-2 survival associations across molecular data types. TRBV10-2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBV10-2 RNA expression–survival associations across cancer types. High TRBV10-2 expression shows unfavorable associations in LGG and KIRP, but favorable associations in HNSC, LUAD, SKCM and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRBV10-2 RNA expression.
This table summarizes TRBV10-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRBV10-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBV10-2 shows lower tumor expression in COAD and BLCA and higher tumor expression in KIRC, STAD, HNSC and LUAD. The KIRC box plot shows higher TRBV10-2 RNA expression in tumor versus normal tissue (log2 FC = +0.567, t-test p < 0.001).
This table shows molecular features associated with TRBV10-2 in patient tissues and cancer cell lines. In patient samples, TRBV10-2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
